Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Issues Final Guidance on Use of Fecal Microbiota for Transplantation November 28, 2022 FDA Announces FY 2019 Fees for Outsourcing Facilities July 31, 2018 EMA Publishes 10-Point Guideline on Preventing Drug Shortages May 18, 2023